Citi raised the firm’s price target on Integra LifeSciences (IART) to $22 from $16 and keeps a Sell rating on the shares. The company reported a somewhat better than expected Q3, the analyst tells investors in a research note. The firm says likely the most important part of the Q3 call was the appointment of Mojdeh Poul as new CEO effective January, “bringing fresh eyes to the organization.”

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

See Insiders’ Hot Stocks on TipRanks >>

Read More on IART:

• Integra LifeSciences Announces Q3 2024 Financial Results

• Nvidia to replace Intel on DJIA, Berkshire reports Q3 results: Morning Buzz

• Morning Movers: Air Transport Services jumps following $3.1B take-private deal

• Integra Lifesciences Appoints Mojdeh Poul as CEO

• Integra LifeSciences narrows FY24 adj. EPS view to $2.41-$2.49 from $2.41-$3.57